JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

32.09 0.79

Buy Sell

Overview

Share price change

24h

Current

Min

31.53

Max

32.62

Key metrics
By Trading Economics
Income	-28M 22M
Sales	4.3M 244M
P/E Sector Avg	10.897 60.328
Profit margin	9.224
Employees	293
EBITDA	-22M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+34.16% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	161M 1.7B
Previous open	31.3
Previous close	32.09

News Sentiment

By Acuity

50%

178 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 kwi 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 kwi 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 kwi 2026, 22:33 UTC

Earnings

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 kwi 2026, 22:17 UTC

Earnings

PLS Executed Offtake Agreement With Ronbay

23 kwi 2026, 22:17 UTC

Earnings

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 kwi 2026, 22:16 UTC

Earnings

PLS Commences Commissioning of Midstream Demonstration Plant

23 kwi 2026, 22:15 UTC

Earnings

PLS Group Reaffirms FY26 Guidance for All Metrics

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 kwi 2026, 22:13 UTC

Earnings

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:11 UTC

Earnings

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 kwi 2026, 22:10 UTC

Earnings

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 kwi 2026, 22:09 UTC

Earnings

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 kwi 2026, 22:08 UTC

Earnings

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 kwi 2026, 22:04 UTC

Earnings

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 kwi 2026, 21:56 UTC

Market Talk

Earnings

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 kwi 2026, 21:27 UTC

Earnings

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 kwi 2026, 21:25 UTC

Earnings

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 kwi 2026, 21:24 UTC

Earnings

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 kwi 2026, 21:24 UTC

Earnings

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 kwi 2026, 21:21 UTC

Earnings

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 kwi 2026, 21:21 UTC

Earnings

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

34.16% upside

12 Months Forecast

Average 42.89 USD 34.16%

High 72 USD

Low 25 USD

Based on 9 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

178 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.